- Home
- PRZO vs KZIA Comparison
PRZO vs KZIA Comparison
Compare PRZO & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRZO | KZIA |
|---|---|---|
| Founded | 2014 | 1994 |
| Country | Israel | Australia |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.5M | 186.7M |
| IPO Year | 2022 | 2002 |
Fundamental Metrics
Financial Performance| Metric | PRZO | KZIA |
|---|---|---|
| Price | $0.72 | $11.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $19.50 |
| AVG Volume (30 Days) | ★ 2.9M | 281.2K |
| Earning Date | 03-26-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.38 | $4.86 |
| 52 Week High | $1.90 | $17.40 |
Technical Indicators
Market Signals| Indicator | PRZO | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 50.34 | 40.81 |
| Support Level | $0.66 | $5.15 |
| Resistance Level | $0.82 | $14.85 |
| Average True Range (ATR) | 0.09 | 1.12 |
| MACD | -0.01 | -0.28 |
| Stochastic Oscillator | 20.04 | 8.50 |
Price Performance
Historical ComparisonAbout PRZO ParaZero Technologies Ltd.
ParaZero Technologies Ltd operates as an aerospace defense company focused on the development of smart, autonomous solutions for the manned and unmanned aerial systems (UAS) industry. The Company develops, manufactures, markets, and sells counter-UAS net-launching platforms designed to protect against hostile drones in both battlefield and urban environments, precision aerial delivery systems for military applications, and smart, autonomous parachute safety systems designed to enable safe flight operations over populated areas and beyond visual line-of-sight. The Company sells its products internationally.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.